Eisai Co., Ltd.

152 clinical trials · Sponsor

Record	Firm	Date
A Study of E6742 in Participants With Systemic Lupus Erythematosus (NCT07515014)	Eisai Co., Ltd.	2026-03-31
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy (NCT06793709)	Eisai Co., Ltd.	2025-07-10
A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures (NCT06657378)	Eisai Co., Ltd.	2024-11-18
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders (NCT05633108)	Eisai Co., Ltd.	2023-03-30
A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder (NCT05594589)	Eisai Co., Ltd.	2022-11-30
A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants (NCT05278676)	Eisai Co., Ltd.	2022-07-01
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants (NCT05278663)	Eisai Co., Ltd.	2022-04-14
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout (NCT05007392)	Eisai Co., Ltd.	2021-12-21
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan (NCT05228158)	Eisai Co., Ltd.	2021-08-16
A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants (NCT04683185)	Eisai Co., Ltd.	2020-12-28
A Study of Lemborexant in Chinese Participants With Insomnia Disorder (NCT04549168)	Eisai Co., Ltd.	2020-11-06
A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants (NCT04609852)	Eisai Co., Ltd.	2020-10-28
A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants (NCT04555733)	Eisai Co., Ltd.	2020-10-26
A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia. (NCT04573556)	Eisai Co., Ltd.	2020-10-17
A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants (NCT04565574)	Eisai Co., Ltd.	2020-10-16
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment) (NCT04724109)	Eisai Co., Ltd.	2020-10-14
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (NCT04572295)	Eisai Co., Ltd.	2020-10-09
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (NCT04568902)	Eisai Co., Ltd.	2020-09-30
Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants (NCT04271488)	Eisai Co., Ltd.	2020-02-27
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion (NCT04238715)	Eisai Co., Ltd.	2020-01-22
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor (NCT04078295)	Eisai Co., Ltd.	2019-09-05
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma (NCT04008082)	Eisai Co., Ltd.	2019-05-14
A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants (NCT03885882)	Eisai Co., Ltd.	2019-04-13
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) (NCT03833700)	Eisai Co., Ltd.	2019-03-05
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy (NCT03754582)	Eisai Co., Ltd.	2018-11-27
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor (NCT03009292)	Eisai Co., Ltd.	2018-08-06
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation (NCT03456726)	Eisai Co., Ltd.	2018-04-09
Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects (NCT03424564)	Eisai Co., Ltd.	2018-03-20
A Study of E7130 in Participants With Solid Tumors (NCT03444701)	Eisai Co., Ltd.	2018-02-05
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (NCT03418922)	Eisai Co., Ltd.	2018-01-16
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects (NCT03402178)	Eisai Co., Ltd.	2017-12-21
Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects (NCT03399734)	Eisai Co., Ltd.	2017-12-18
Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (NCT03548311)	Eisai Co., Ltd.	2017-11-01

Track Eisai Co., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.